Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

NCT01837511 · clinicaltrials.gov ↗

COMPLETED

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Interventions

OTHER: Data acquisition and analysis

Sponsor

GlaxoSmithKline